New combo therapy aims to turn inoperable liver cancer into surgical candidates
NCT ID NCT07012798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a sequence of treatments—chemotherapy infused into the liver, two drugs (durvalumab and bevacizumab), and targeted radiation—can shrink advanced liver cancer enough to allow surgery. About 30 adults with liver cancer that cannot currently be removed will receive this combination. The goal is to see if the cancer becomes operable and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianjin Cancer Hospital Airport Hospital
RECRUITINGTianjin, Tianjin Municipality, 300308, China
Contact Phone: •••-•••-•••• Email: •••••@•••••